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Acute severe lower respiratory tract infections (LRTIs) continue 
to be a major cause of mortality (13%) and morbidity globally[1,2] 
and in South Africa (SA).[1] Reid et al.[3] showed that pneumonia 
was the main cause of death (25%) in children aged <5 years in the 
Metro West health district of the Western Cape Province of SA.[3] In 
many middle- to low-income countries with resource limitations, 
the number of child deaths resulting from severe pneumonia 
(related to hypoxaemia and respiratory failure) remains high despite 
implementation of international and local guidelines.[4] Additional 
respiratory support, important in the care of critically ill children, 
is often unavailable or is perceived as being neither feasible nor safe 
in resource-limited settings.[4,5] The use of non-invasive ventilation 
for respiratory support, including nasal continuous positive airway 
pressure (CPAP) and high-flow nasal cannula (HFNC) therapy, in 
and outside the paediatric intensive care unit (PICU) is increasing. [5,6] 
There is limited evidence to support the use of HFNC in children 
outside the PICU setting and in conditions other than bronchiolitis.[7]
The probable mechanisms of action of HFNC include heating and 
humidification of inspired air, nasopharyngeal carbon dioxide wash-
out, reduction in upper airway resistance, and provision of positive 
distending pressure.[8-12] The current paucity of data on the variable 
positive distending pressure provided by HFNC raises clinical safety 
concerns,[7] and many modern HFNC devices therefore now have 
pressure-limiting valves. However, more robust physiological studies 
are needed.[7]
A pioneering, contextually relevant study from Bangladesh 
showed that outcomes in terms of ‘treatment failure’ (defined as two 
or three of the following characteristics: severe hypoxia, signs of severe 
clinical distress, or respiratory acidosis on blood gas analysis) were no 
worse in patients with severe pneumonia who received HFNC than 
in those who received bubble CPAP, but mortality rates were higher 
in the low-flow nasal cannula (LFNC) and HFNC groups, indicating 
a potential risk of harm associated with these modalities.[13] Various 
observational studies have shown that HFNC reduces respiratory rates 
and the effort of breathing in infants with bronchiolitis, has very few 
reported complications, and is well tolerated.[7]
Commercial HFNC devices and circuits are expensive. 
Guaranteeing that a clinically effective and cost-effective form of 
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Background. High-flow nasal cannula (HFNC) oxygen is a non-invasive alternative to nasal continuous positive airway pressure (CPAP) 
therapy for infants and children requiring respiratory support. There is a paucity of data to support its use in children, with no published 
data from sub-Saharan Africa.
Objectives. To describe the outcomes of and adverse events related to HFNC in the first year of its use in a level 2 (L2) general paediatric 
ward, and to compare these outcomes with those of a historical cohort when this intervention was unavailable.
Methods. This retrospective descriptive study included children aged <13 years who received HFNC in the first 12 months after its 
introduction (HFNC-availability group, n=66). Demographic data, clinical characteristics and outcomes (death, treatment failure, length 
of HFNC and HFNC-related adverse events) were assessed. A comparative description of children who required transfer to level 3 (L3) for 
any form of respiratory support (other than the available standard low-flow oxygen) during the 12-month period prior to HFNC availability 
(pre-HFNC group, n=54) was made. All analyses were performed in the paediatric wards, New Somerset Hospital, Cape Town, South Africa. 
Outcomes were compared using standard descriptive and comparative statistics.
Results. The median age of the cohort was 5 months (interquartile range (IQR) 1.9 - 14.6). Sixteen children (13.3%) were malnourished, 
10 (8.3%) were HIV-infected, and 30 (25.0%) had been born prematurely. The most common diagnoses were pneumonia, bronchiolitis and 
asthma. Asthma, anaemia and cardiac abnormalities were the most prevalent underlying comorbidities. Two children died in each group. 
All 54 children in the pre-HFNC group were transferred to L3; 38 (70.4%) needed CPAP or invasive ventilation. In the HFNC-availability 
period, 85 children were assessed as needing more than standard low-flow oxygen therapy: of the 19 immediately transferred to L3, 
17 (89.4%) received CPAP or invasive ventilation; of the 66 who received HFNC at L2, 16 (24.2%) subsequently required transfer to L3 for 
CPAP or invasive ventilation. The median duration of HFNC was 46.3 hours (IQR 19.5 - 93.5) overall, and it was 12 hours (IQR 4 - 28) and 
58.5 hours (IQR 39.5 - 106) for those who failed or were successfully managed on HFNC, respectively. No HFNC-related serious adverse 
events were recorded.
Conclusions. HFNC is a safe, effective, feasible option for non-invasive ventilation of children with respiratory illnesses in a resource-limited 
L2 setting. A greater proportion of children with lower respiratory tract infections in the HFNC-availability group than in the pre-HFNC 
group required support, but the intervention reduced the bed pressure on L3. Improved ways to identify HFNC failures would be beneficial.
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respiratory support is delivered in a safe environment and that 
children requiring escalation of respiratory support are identified 
early is crucial to the appropriate utilisation of a new intervention, 
especially in a resource-limited environment. Consequently, more 
research is needed to document efficacy and safety in various clinical 
scenarios.
Objectives
The donation in 2015 of two commercial HFNC devices (Fisher 
and Paykel Airvo 2) to the general paediatric ward at New Somerset 
Hospital (NSH), a level 2 (L2) hospital in the Metro West subdistrict 
of Cape Town, SA, afforded the pragmatic opportunity to review 
this new intervention. Prior to the availability of on-site HFNC, 
all children who may have required additional respiratory support 
(HFNC, CPAP or intermittent positive-pressure ventilation (IPPV)) 
were transferred by ambulance to a level 3 (L3) children’s hospital that 
has dedicated high-care and PICU facilities. The main objective of 
this study was to document the first year of experience using HFNC 
by describing the demographic and clinical characteristics of children 
who were initiated on HFNC oxygen therapy on site, evaluating their 
response to the intervention and assessing its safety. Our secondary 
objective was to compare the outcomes in this group with those in a 
group transferred to L3 for respiratory support during the year before 
HFNC was available on site.
Methods
Study design and participants
This was a retrospective descriptive study of children aged <13 years 
hospitalised with a respiratory condition for which they were 
managed with HFNC oxygen therapy in the general paediatric 
ward of NSH during the first 12 months of its availability (1 August 
2015 - 31 July 2016). Comparison was made with children aged 
<13  years who required transfer for additional respiratory support 
for respiratory distress during the 12 months prior to the availability 
of HFNC oxygen therapy at the same institution (1 August 2014 - 
31 July 2015).
Children commenced on HFNC oxygen according to depart-
mental guidelines were identified from the ethics-approved 
NSH High-Flow Nasal Cannula Registry (University of Cape 
Town Human Research  Ethics  Committee (UCT HREC) ref. no. 
R051/2015). Children transferred to L3 care for respiratory support 
during the preceding year were identified from existing routine 
morbidity and mortality records of the Department of Paediatrics 
at NSH. The UCT HREC granted ethical approval for this study and 
waived the need for informed consent owing to its retrospective 
nature (ref. no. 534/2016), and the NSH CEO gave permission to 
use patient data.
Setting
NSH is a 330-bed L2 hospital, i.e. there are specialists on 
site, but no subspecialty or intensive care service is offered. 
The paediatric population served comprises ~100  000 children, 
mostly from middle and lower socioeconomic backgrounds and 
many from informal housing areas. There is no PICU on site, 
and children requiring advanced respiratory support need to be 
transported to an L3 hospital where subspecialty services and 
PICU facilities are available. The L3 hospital is ~30 minutes away 
by road ambulance transport. Staffing (both nurse and doctor 
numbers) remained unchanged during the two study periods. All 
children with respiratory distress requiring oxygen therapy are 
closely monitored in the paediatric ward and receive supportive 
care, including nasogastric tube feeding if in moderate or severe 
respiratory distress.
HFNC system and protocol
The Fisher and Paykel Airvo 2 system (Fisher & Paykel Healthcare 
Ltd, New Zealand) is used at NSH, with a humidifier and age- and 
weight-appropriate Fisher and Paykel nasal cannulas. The NSH 
HFNC oxygen guideline was adapted for local use from the Royal 
Children’s Hospital, Melbourne, guideline.[14] Starting flow rates are 
based on the weight of the child (<10 kg: 2.0 L/kg/min and >10 kg: 
2.0 L/kg/min for the first 10 kg plus 0.5 L/kg/min for each kg above 
10 kg, with a maximum flow rate of 50 L/min). The decision to 
commence HFNC always involves a senior paediatrician. Both 
nurses and doctors working in the ward received basic training in 
the use of the device and the children receiving HFNC had hourly 
observations performed, including pulse oximetry and measurement 
of the respiratory rate (RR) and heart rate (HR), in a high-care bed.
The indications for HFNC in the guideline include use in children 
with moderate-to-severe respiratory distress with hypoxaemia 
(peripheral oxygen saturation <90%) despite standard low-flow 
oxygen (provided by nasal prong or face-mask) due to common 
childhood respiratory illnesses such as community-acquired 
pneumonia, bronchiolitis, and asthma exacerbations. Absolute 
contraindications to HFNC use include the need for immediate 
invasive respiratory support, infants or children with non-patent 
nasal passages, and infants weighing <3 kg.
Children receiving HFNC were monitored and reviewed both 
30 minutes and ~2 hours after being initiated on HFNC to determine 
whether transfer to L3 and/or additional support was required. No 
improvement in the RR and HR (>20% reduction not achieved), 
inability to wean the inspired oxygen concentration to <40%, or signs 
of worsening respiratory distress indicated treatment failure and the 
need to transfer the child for advanced respiratory support.
Data collection and definitions
The medical folders of identified patients were drawn from the 
medical records department and reviewed, and relevant data were 
entered into an electronic data capture sheet (Microsoft Access 
version 2013; Microsoft, USA). Any results and details not recorded 
in the medical folder were searched for through the electronic 
National Health Laboratory Service and Clinicom platforms.
The data collected comprised basic demographic information, 
diagnosis, underlying comorbidity, birth weight, gestational age, 
and HIV and nutritional status. Diagnosis was as assigned by 
the attending ward doctor according to standard definitions of 
pneumonia (cough with fast breathing and/or chest in-drawing) or 
bronchiolitis (associated preceding coryzal illness with predominant 
features of hyperinflation with crackles and/or wheezing). HIV 
status was classified as uninfected, exposed but uninfected, and 
infected. Owing to the small number of HIV-infected children, 
no distinction was made according to whether these children 
were taking combined antiretroviral treatment (cART), were pre-
cART or had defaulted cART, or according to their immunological 
or virological status. The nutritional status of each child was 
determined by the World Health Organization (WHO) weight-for-
age (WAZ) and weight-for-height/length (WHZ) z-scores. These 
z-scores were calculated using the ‘zanthro’ function of Stata/IC 13.0 
statistical software (StataCorp, USA), with 2007 UK WHO term 
and preterm growth charts used for reference (birth: British 1990 
Growth Reference, reanalysed 2009; postnatal: WHO Child Growth 
Standards; 4 - 20 years: British 1990 Growth Reference – information 
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accessible to registered Stata users). Prematurity was taken into 
account in the calculation of the z-scores. Malnutrition was defined 
as a WHZ score <–2 (moderate wasting). The method of delivery of 
standard low-flow oxygen support received by transferred children 
in the pre-intervention group was collected.
We obtained the baseline number of monthly admissions from 
routine departmental data on total admissions for acute LRTIs in 
children aged <5 years. Despite being restricted to children aged <5, 
we thought that this would be a reasonable approximation of the total 
number of acute LRTI admissions given that 90% of our total cohort 
was <5 years of age, and the older group were mostly children with 
asthma who would not be counted in the baseline data.
Data analysis
Data analysis was performed using Stata/IC 13.0 statistical software. 
Continuous data tested for normality using the Shapiro-Wilks test 
are presented as medians (interquartile range (IQR)) or means 
(standard deviation (SD)) for non-normally and normally distributed 
data, respectively. Medians and means were compared between 
groups using the Wilcoxon rank-sum or Student’s t-test, respectively. 
Categorical data are presented as frequencies and percentages, with 
the χ2 or Fisher’s exact test used for comparison between groups, as 
appropriate. For all tests, p<0.05 was considered significant.
Outcome measures
Outcomes described in the HFNC group included the length of time 
receiving HFNC, any severe adverse events associated with HFNC 
use, and success or failure of the intervention. Success was defined 
as no need for escalation of respiratory support, while failure was 
defined as needing further non-invasive (CPAP) or invasive (IPPV) 
respiratory support within 48 hours of transfer, or death during 
admission. The intervention’s success and failure outcomes were then 
compared with similar outcomes in the pre-intervention (pre-HFNC) 
group.
Results
During the first 12 months of on-site availability of HFNC in the 
general paediatric ward (1 August 2015 - 31 July 2016), 66 infants 
and children received HFNC oxygen therapy. In the pre-HFNC-
availability period (1 August 2014 - 31 July 2015), during which only 
standard low-flow oxygen respiratory support (nasal prong oxygen or 
face-mask oxygen) was available, 54 children required transfer to an 
L3 hospital for further respiratory support.
Demographic and clinical characteristics
The median age of the whole study cohort was 5 months (IQR 1.9 - 
14.6), with a slight male preponderance (Table 1). Of the study 
Table 1. Demographic and clinical characteristics
Total (N=120)
Pre-HFNC-availability  
group (N=54)
HFNC-availability  
group (N=66) p-value
Age (months), median (IQR) 5.0 (1.9 - 14.6) 3.2 (1.4 - 13.2) 6.4 (2.5 - 14.9) 0.057
Age <5 years, n (%) 107 (89.2) 47 (87.0) 60 (90.9) 0.49
Sex, n (%) 0.60
Male 68 (56.7) 32 (59.3) 36 (54.6)
Female 52 (43.4) 22 (40.7) 30 (45.4)
Nutritional status
WAZ, mean (SD) –0.98 (1.96) –1.38 (1.90) –0.65 (1.97) 0.04
WAZ <–2, n (%) 37 (30.8) 23 (42.6) 14 (21.2) 0.01
HAZ, median (IQR) –0.53 (–1.57 - 0.28) –0.53 (–1.56 - –0.02) –0.48 (–1.57 - 0.57) 0.69
HAZ <–2, n (%) 22/114 (19.3) 9/48 (18.8) 13/66 (19.7) 0.90
WHZ, median (IQR) –0.60 (–1.38 - 0.86) –1.17 (–2.09 - 0.60) –0.23 (–0.88 - 0.92) 0.002
WHA <–2, n (%) 16/106 (15.1) 14/45 (31.1) 3/61 (3.3) <0.001
HIV status, n (%) 0.02*
Exposed 23 (19.2) 13 (24.1) 10 (15.2)
Infected 10 (8.3) 8 (14.8) 2 (3.0)
Uninfected 87 (72.5) 33 (61.1) 54 (81.8)
Comorbidities, n (%) 0.14*
Anaemia 10/58 (17.2) 3/29 (10.3) 7/29 (24.1)
Asthma 14/58 (24.1) 5/29 (17.2) 9/29 (31.0)
CLD 4/58 (6.9) 3/29 (10.3) 1/29 (3.5)
HIV-infected 10/58 (17.2) 8/29 (27.6) 2/29 (6.9)
Cardiac 7/58 (12.1) 5/29 (17.2) 2/29 (6.9)
Probable TB 4/58 (6.9) 1/29 (3.5) 3/29 (10.3)
Other 9/58 (15.5) 4/29 (13.8) 5/29 (17.2)
Prematurity, n (%) 30 (25.0) 18 (33.3) 12 (18.2) 0.057
Diagnosis, n (%) 0.13*
Pneumonia 84 (70.0) 42 (77.8) 42 (63.6)
Bronchiolitis 23 (19.2) 6 (11.1) 17 (25.8)
Asthma 13 (10.8) 6 (11.1) 7 (10.6)
HFNC = high-flow nasal cannula oxygen therapy; IQR = interquartile range; WAZ = weight-for-age z-score; HAZ = height (or length)-for-age z-score; WHZ = weight-for-height (or length) 
z-score; SD = standard deviation; CLD = chronic lung disease; TB = tuberculosis.
*Fisher’s exact test.
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population for whom nutritional data were 
available (106/120), 15.1% (16/106) were 
moderately or severely malnourished, with 
a greater proportion in the pre-HFNC 
group (31.1%, 14/45) than in the HFNC 
group (3.3%, 3/61) being malnourished. A 
significantly greater proportion of children 
were HIV-infected or HIV-exposed in the 
pre-HFNC group than in the HFNC group. 
Among children with underlying comorbid 
conditions (n=58), asthma and anaemia 
were the most common, being present in 
24.1% (14/58) and 17.2% (10/58) of these 
children, respectively. In addition, 12.1% 
(7/58) had an underlying congenital cardiac 
abnormality. The most common diagnosis 
was pneumonia (n=84, 70.0%), followed by 
bronchiolitis, then asthma. Of children aged 
<5 years, the majority (n=82, 76.6%) had 
pneumonia, whereas in the older age group 
(>5 years) the majority (n=11, 84.6%) had 
asthma. A quarter of the study population 
had been born prematurely.
Comparison of outcomes between 
the groups
Death during admission
Two children died in each group, 3.7% in 
the HFNC-availability group and 3.0% in 
the pre-HFNC-availability group. The 
deaths in the HFNC-availability group were 
un related to the intervention. In this group, 
the children who died were 4 and 13 months 
old, HIV-unexposed and uninfected, not 
malnourished, and had an initial diagnosis 
of pneumonia. The 4-month-old child had 
no underlying comorbidities and, within 12 
hours of commencing HFNC, was transferred 
to L3 for invasive respiratory support in the 
PICU; he died 8 weeks later of intractable 
respiratory failure secondary to severe 
bronchopneumonia. The 13-month-old child 
had significant underlying comorbidities – 
Down syndrome, hypo thyroidism, gastro-
oesophageal reflux disease and evidence of 
chronic lung disease. He received HFNC 
oxygen for 9 days during his stay and was 
weaned off successfully, but unexpectedly 
died of aspiration at the regional hospital 
after a 5-week hospital admission.
Need for escalation of respiratory support
Fig. 1 shows the study flow. In the pre-
HFNC-availability group, 54/835 children 
(6.5%) admitted for acute LRTIs were 
assessed as needing transfer to L3 for possible 
additional respiratory support. Of the 54 
children transferred, 38 (70.4%) required 
CPAP or IPPV within 48 hours of transfer, 
or died, while 16 (29.6%) received HFNC or 
remained on nasal prong oxygen at L3.
In the HFNC availability group, 85/604 
(14%) of children admitted for acute LRTIs 
were assessed as needing more than standard 
low-flow oxygen therapy; 66 (10.9%) were 
initiated on HFNC in the general ward 
at NSH, while 19 (3.1%) were assessed 
as needing more support than could be 
provided by HFNC and were transferred 
directly to L3. Overall, 33 children (5.5%) 
admitted for acute LRTIs were transferred to 
L3. Of the 19 children assessed as requiring 
transfer to L3 without being offered on-site 
HFNC oxygen, the majority (n=17, 9.4%) 
received CPAP or IPPV at the referral facility, 
while 2 (10.5%) were managed with HFNC 
or nasal prong oxygen. Of the 66 children 
initiated on HFNC in the general ward, 
50 (75.8%) were successfully managed and 
weaned off HFNC and discharged home. 
The other 16 (24.2%) were assessed as not 
settling on HFNC and were transferred to 
L3 within 48 hours of being on HFNC. 
At L3 they received either CPAP or IPPV; 
one of these children died after a period of 
prolonged ventilation.
The HFNC group
Length of time receiving HFNC
The overall median length of time on 
HFNC was 46.3 hours (IQR 19.5 - 93.5). 
Of the 16 children who failed HFNC at 
NSH, the median length of time on HFNC 
was 12  hours (IQR 4 - 28). Among those 
who were successfully managed on HFNC, 
the median length of time on HFNC was 
58.5 hours (IQR 39.5 - 106). Four children 
required HFNC for longer than 7 days (range 
9 days (231 hours) - 13 days (322  hours)); 
one of these patients died.
Serious adverse effects in the HFNC group
No pneumothoraces, episodes of gastric or 
abdominal distension, mucosal injuries or 
infections were documented for any of the 
children receiving HFNC oxygen therapy 
in the general ward of NSH during the first 
12 months of its use. Of the infants who failed 
HFNC at L2 and were transferred to L3, most 
were boys (n=12, 75.0%) and the median age 
of the 16 infants was 6.7 months; 10 (62.5%) 
were <6 months old. The attending doctor’s 
interpretation of the chest radiographs was 
that 15 of the infants had hyperinflation and 
either focal areas of opacification or changes 
consistent with bronchopneumonia. At L3, 
15 children had blood cultures performed 
(all results were negative) and 12 (75.0%) had 
a nasopharyngeal aspirate (NPA) coll ected. 
Two children’s NPA specimens were negative 
and 10 (83.3%) tested positive for respiratory 
viruses: 5 were positive for adenovirus, 3 were 
positive for both adenovirus and respiratory 
2015
1 August 2014 - 31 July 2015
Total admissions for acute 
LRTIs in children aged <5 y*
N=835
Deemed to require more than 
NP or mask O2
Transferred to L3
Success 
(on HFNC 
or 
NP O2)
n=16 (29.6%)
Failure 
(required
 CPAP 
or IPPV on 
arrival 
or within 
48 h of 
being on 
HFNC O2 , 
or died)
n=38 
(70.4%)
Died
n=2 (3.7%)
2016
1 August 2015 - 31 July 2016
Total admissions for acute 
LRTIs in children aged <5 y*
N=604
Deemed to require HFNC O2
n=66 (10.9%)
Deemed to require more than 
HFNC O2
n=19 (3.1%)
Initiated on HFNC O2 at NSH Transferred to L3
Success 
(on HFNC O2)
n=50 
(75.8%)
Failure 
(required 
transfer to 
L3 for CPAP or 
IPPV on arrival 
or within 48 h of 
being on HFNC 
O2, or died)
n=16 (24.2%)
Died
n=2 (3.0%)
Received HFNC 
or NP O2
n=2 (10.5%)
Received 
CPAP or 
IPPV
n=17 
(89.4%)
Fig. 1. Participant flow. (y = years; h = hours; LRTI = lower respiratory tract infection; NP = nasal 
prong; O2 = oxygen; L3 = level 3 hospital; HFNC = high-flow nasal cannula; CPAP = continuous positive 
airway pressure; IPPV = intermittent positive-pressure ventilation; NSH = New Somerset Hospital; 
*Number of admissions for children aged ≥5 y not available (89% of the overall cohort was <5 y old).)
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syncytial virus (RSV), one specimen was only RSV-positive, and one 
was influenza virus-positive. The vital sign monitoring data (HR, RR, 
FiO2 and oxygen saturation) of the 16  children who failed HFNC, 
recorded hourly at L2, were reviewed, and no consistent pattern 
predicting failure was observed.
Discussion
This is the first study from sub-Saharan Africa documenting the 
safe, effective use of HFNC in a general paediatric ward setting. We 
identified no complications and demonstrated that an L2 hospital has 
the capacity to manage children who require more than standard low-
flow oxygen respiratory support, reducing pressure on L3 services.
Pneumonia was the predominant diagnosis in the overall study 
population, reflecting current evidence that pneumonia is the leading 
cause of morbidity and mortality in children in SA.[2] A significant 
proportion of the children in this study population had wasting 
(WHZ <–2) and 25.0% had been born prematurely. Asthma, anaemia 
and cardiac abnormalities were the most prevalent underlying 
comorbidities. Unlike the study by Chisti et al.,[13] in the present study 
an underlying cardiac abnormality was not a contraindication to the 
use of HFNC despite very limited evidence for its efficacy in paediatric 
cardiac patients.[15] One child with a cardiac abnormality died, but not 
while receiving the intervention. Although the numbers were small, 
HFNC was successfully used in 4 children with underlying congenital 
heart disease as respiratory support during an acute admission for 
pneumonia.
The proportion of HIV-infected children was significantly lower in 
the HFNC availability group than in the pre-HFNC group; although 
it is unlikely, this may reflect the effectiveness of ongoing strategies 
to prevent perinatally acquired HIV infection in SA via prevention of 
mother-to-child transmission and the early initiation of cART.
HFNC use did not appear to affect the number of deaths in 
the two groups, a finding consistent with that reported by Chisti 
et al.[13] Mortality rates were very low for both groups (0.2 and 
0.3  deaths/100 admissions), so this study was underpowered to 
make any meaningful conclusions with regard to the effect of 
HFNC on mortality.
Transferring children from L2 to L3 hospitals puts a significant 
strain on limited resources, including the emergency medical services 
and L3 bed capacity. Whether a transfer is warranted and safe raises 
anxiety and concern among staff at the referring facility. A much 
higher proportion of children required additional respiratory support 
during the year when HFNC was available than during the preceding 
year (14.1% v. 6.5%). It is possible that this was due to a ‘very bad 
respiratory season’ (anecdotal). It is unlikely that it was simply because 
of availability of HFNC, as the intervention had been available at the 
L3 facility in the preceding years, criteria regarding requirements for 
additional respiratory support were the same for both institutions, 
and children identified as needing the intervention would have been 
transferred. The transfers would not have been accepted by the L3 
institute if deemed unnecessary, and all decisions were consultant led. 
Therefore, almost two-thirds of the children who would potentially 
have been transferred prior to the availability of HFNC at L2 were 
successfully managed at L2 in 2016, reducing staff anxiety about 
observing and transferring very ill children, and decreasing the strain 
on the emergency medical services and L3 bed capacity.
Although the total number of cases of severe acute asthma was 
small, children receiving HFNC as part of management responded 
well with no adverse events. It could be proposed that use of HFNC 
be included as an addition to current standard asthma management 
guidelines as an adjunct at the stage of using intravenous medication 
(salbutamol and magnesium sulphate) in severe acute exacerbations 
not responding to standard nebulised therapy.
A lower proportion overall of children transferred after receiving 
initial HFNC at L2 needed non-invasive or invasive respiratory 
support at L3 once transferred, compared with children transferred 
on/after receiving only standard LFNC oxygen. This supports the 
findings of Wing et al.[16] that the introduction of HFNC reduced the 
need for intubation and the need for non-invasive/invasive retrieval 
during interhospital transfer. Because we used retrospective data from 
the pre-HFNC-availability cohort, we do not have information on 
how long children were at the referring facility prior to transfer and 
whether this could have affected outcome. Fewer children requiring 
high-care/PICU non-invasive or invasive ventilatory support at L3 
also reduces the strain on limited L3 resources (high-care and PICU 
bed capacity and nursing requirements), justifying the provision of 
HFNC therapy at lower levels of care. In the HFNC-availability group, 
the majority of children assessed as needing more support than that 
provided by HFNC (i.e. those who did not meet the requirements of 
the protocol for safe use of HFNC at L2) ultimately required either 
CPAP or IPPV at L3. These findings support the current clinical 
practice and endorse the current protocol.
The NSH HFNC protocol states that if there is no objective 
response to HFNC (reduction in HR and RR within 2 - 4 hours), the 
intervention has failed and the child needs transfer for additional 
support (CPAP or IPPV). The median length of time that HFNC 
oxygen was provided was 12 hours, which may indicate that this 
protocol was not strictly adhered to and that an earlier decision to 
transfer may have been preferable. It could also reflect natural disease 
progression with some patients deteriorating during the admission, 
requiring increased support because of hypoxia or tiring, or that 
some patients such as asthmatics needed shorter periods of support.
The absence of any recorded serious adverse events related to 
the use of HFNC in our general paediatric ward is encouraging and 
concurs with the literature reporting few adverse effects.[15,17,18] Lack 
of adverse events further supports the use of HFNC as an attractive 
option, but strict adherence to protocol is required. Although they 
were reviewed, detailed analysis of the group of children who failed 
HFNC at L2 was not done because we did not have the corresponding 
data from children who did not fail for comparison. However, there 
appeared to be an association between the doctor’s assessment of 
RR at initiation of HFNC and the documented RR at transfer, with 
patients who were transferred remaining significantly tachypnoeic. 
The high proportion of infants with severe pneumonia needing 
transfer to L3 for respiratory support who had adenovirus on NPA 
supports the recently published study by Zampoli and Mukuddem-
Sablay[19] demonstrating that adenovirus is an important cause of 
severe pneumonia necessitating ICU admission in young children 
in SA.
Study limitations
This study has several limitations. Its design was retrospective, using 
an unmatched, historical comparator group. However, the criteria 
for additional respiratory support were the same and the staff was 
unchanged. Although the time period was similar (including one 
autumn/winter respiratory season in both groups) and the referral 
areas and admission criteria were the same, it seems that there were 
more admissions in the first group and that the severity of illness 
necessitating additional respiratory support was greater in the second 
group. Analysis of the group of children who failed HFNC at L2 was 
not included, as we did not have corresponding data from children 
who did not fail, for comparison.
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Conclusions and recommendations
HFNC is a safe, effective, feasible option for non-invasive respiratory 
support in a relatively resource-limited setting as an adjunct in 
the management of respiratory illnesses in children, with reduced 
work of breathing and respiratory rates in those children who were 
successfully managed in a general paediatric ward. The lack of 
serious adverse events is encouraging, but there is a need to refine 
recognition of early failures and to avoid delays in transfer. A detailed 
cost analysis was not done, but despite the relative cost of disposables 
and equipment, broader cost reductions are anticipated: decreased 
inter-hospital transfers, avoidance of L3 admissions, and reduced bed 
pressure in a setting known to have a shortage of PICU and high-care 
space. Results of ongoing international randomised clinical trials 
are eagerly anticipated to further guide appropriate use in similar 
settings.
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